Prospective evaluation of the significance of dose adjustment in rituximab plus CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma

Prospective evaluation of the significance of dose adjustment in rituximab plus CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma - PEARL study

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025569

Enrollment

Registered

2017-01-10

Start date

2017-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse large B cell lymphoma

Interventions

Rituximab plus dose-adjusted CHOP chemotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) histologically diagnosed diffuse large B cell lymphoma by WHO classification 2008. (2) CD20 positive (3) No previous chemotherapy or radiotherapy. (4) Performance Status: between 0 and 3. (5) No organ dysfuction; neutrophil count>1000/mm3 platelet count >100000, AST and ALT level <5 times the upper limit of the normal range, total bilirubin level<2.0 mg/dl, eGFR>30ml/min no cardiac dysfunction. SpO2>92 (6) Understanding and agreement of written informed consent.

Exclusion criteria

Exclusion criteria: (1)testis,CNS invasion/IVL,transformation from loe grade lymphoma (2)HIV infection (3)severe infection (4)Psycological disorder like schizophrenia. (5)Active or non-curable synchronous malignancy

Design outcomes

Primary

Measure	Time frame
Progression-free survival	—

Countries

Japan

Contacts

Public ContactAkiko Meguro

Tochigi Cancer Center Division of hematology

akmeguro@tochigi-cc.jp028-658-5151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026